Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs
Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.
You may also be interested in...
With Akero’s FGF21 analog showing ability to reduce fibrosis and resolve non-alcoholic steatohepatitis, some analysts think classmate BIO89-100 could yield a better overall profile. NASH data are starting to pour in.
Already partnered with Regeneron in NASH, Alnylam unveils a new R&D collaboration in eye, CNS and liver indications, after Alnylam and Sanofi end the research phase of their relationship.
Along with last week's acquisition of three NASH candidates from Lilly by Terns, NASH remains a heavily crowded R&D space as the European Association for the Study of the Liver annual meeting approaches.